Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review ArticleDrug TherapyFree Preview

Trastuzumab — Mechanism of Action and Use in Clinical Practice

List of authors.
  • Clifford A. Hudis, M.D.

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Dr. Hudis reports receiving lecture and consulting fees from Genentech, consulting fees from GlaxoSmithKline, and a grant from Kosan Biosciences. No other potential conflict of interest relevant to this article was reported.

I thank Tiffany Traina, M.D., for her editorial review and assistance in the preparation of the manuscript.

Author Affiliations

From the Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.

Address reprint requests to Dr. Hudis at the Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., P.O. Box 206, New York, NY 10021, or at .

Print Subscriber? Activate your online access.